Zhi Tong Cai Jing·2025-11-18 08:41Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Chaohui Pharmaceutical Co., Ltd., has received acceptance for the drug registration application of Compound Polyethylene Glycol (3350) Electrolyte Powder by the National Medical Products Administration, indicating a significant step in expanding its product portfolio in the chronic constipation treatment market [1] Group 1: Company Developments - The drug is intended for the treatment of chronic constipation, excluding constipation caused by organic diseases [1] - The acceptance of the drug registration application marks a crucial milestone for the company in the pharmaceutical sector [1] Group 2: Market Potential - According to IQVIA CHPA data, the projected sales revenue for Compound Polyethylene Glycol Electrolyte Powder in mainland China (excluding Hong Kong, Macau, and Taiwan) is approximately RMB 873 million in 2024 [1]